BidaskClub upgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a sell rating to a hold rating in a research report report published on Friday, BidAskClub reports.

A number of other equities analysts also recently issued reports on the company. Citigroup cut their price target on Alexion Pharmaceuticals from $180.00 to $165.00 and set a buy rating for the company in a research note on Thursday, May 23rd. Goldman Sachs Group reiterated a neutral rating and set a $142.00 price target on shares of Alexion Pharmaceuticals in a research note on Thursday, May 23rd. ValuEngine downgraded Alexion Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, August 8th. Wedbush assumed coverage on Alexion Pharmaceuticals in a research note on Wednesday, May 22nd. They set an outperform rating and a $173.00 price target for the company. Finally, Zacks Investment Research cut shares of Alexion Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, May 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $162.88.

ALXN stock opened at $112.68 on Friday. The company has a market capitalization of $25.27 billion, a P/E ratio of 15.89, a price-to-earnings-growth ratio of 1.04 and a beta of 1.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86. The business has a 50-day simple moving average of $118.22 and a two-hundred day simple moving average of $126.61.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The company’s quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 EPS. As a group, sell-side analysts forecast that Alexion Pharmaceuticals will post 9 earnings per share for the current fiscal year.

In related news, Director Bros. Advisors Lp Baker sold 300,000 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $123.74, for a total value of $37,122,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the sale, the executive vice president now directly owns 29,627 shares in the company, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,567 shares of company stock worth $53,420,869. Insiders own 4.08% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Alexion Pharmaceuticals by 10.4% in the 1st quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock worth $3,939,729,000 after purchasing an additional 2,746,055 shares during the period. Vanguard Group Inc. raised its holdings in shares of Alexion Pharmaceuticals by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock worth $2,180,703,000 after purchasing an additional 211,960 shares during the period. BlackRock Inc. raised its holdings in shares of Alexion Pharmaceuticals by 1.2% in the 2nd quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock worth $2,125,230,000 after purchasing an additional 199,298 shares during the period. Jennison Associates LLC raised its holdings in shares of Alexion Pharmaceuticals by 17.3% in the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after purchasing an additional 1,512,545 shares during the period. Finally, Clearbridge Investments LLC raised its holdings in shares of Alexion Pharmaceuticals by 12.9% in the 1st quarter. Clearbridge Investments LLC now owns 5,810,033 shares of the biopharmaceutical company’s stock worth $785,400,000 after purchasing an additional 665,574 shares during the period. 92.67% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: Strike Price

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.